Dr. Cohen received his Ph.D. in  retinal neuroanatomy in 1987 at U. Penn. Med. School in the lab of Dr. Peter Sterling. After post-doctoral fellowships at UCLA and the Univ. of Minn. with Gordon Fain, and Robert Miller, he joined the faculty of the Ophthalmology Dept at Yale University in 1992. After a visiting professorship at Harvard University with Dr. John Dowling, he joined FDA in 2003.

My medical device research focuses on projects that evaluate the safety and efficacy of cutting edge neuroprosthetic therapies for blindness. Our lab is currently developing novel methods of evaluating new electrical and optical stimulation therapies for retinal neurons, particularly using imaging methods of retinal tissue in real time.

Research Methods
Patch Clamping
Optical Coherence Tomography
Confocal Microscopy
Impedance Spectroscopy of Neural Tissue
Light-Stimulation of Retinal Tissue
Research Interests
Retinal Prostheses for the Blind
Bioimpedance of Visual System Tissues
Optogenetics
Real-Time Retinal Optical Coherence Tomography of Drug Effects on the Retina
Ganglion Cell Function and Microglia Activation by Stimulus Electrodes
Dr. Ethan Cohen
Food and Drug Administration, Room 1204, WO62, White Oak Federal Research Center, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Neuroscience and Cognitive Science
Email
ethan.cohen [at] fda.hhs.gov